Ana Sandoval‐Rodriguez, Hugo Christian Monroy‐Ramirez, Alejandra Meza‐Rios, Jesus Garcia‐Bañuelos, Jose Vera‐Cruz, Jorge Gutiérrez‐Cuevas, Jorge Silva‐Gomez, Bart Staels, Jose Dominguez‐Rosales, Marina Galicia‐Moreno, Monica Vazquez‐Del Mercado, Jose Navarro‐Partida, Arturo Santos‐Garcia, Juan Armendariz‐Borunda – 16 January 2020 – Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features.

Gopanandan Parthasarathy, Xavier Revelo, Harmeet Malhi – 14 January 2020 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected in a clinical and histologic spectrum where some patients develop isolated steatosis of the liver, termed nonalcoholic fatty liver, whereas others develop hepatocyte injury, ballooning, inflammation, and consequent fibrosis, termed nonalcoholic steatohepatitis (NASH).

Heather Bradley, Eric W. Hall, Elizabeth M. Rosenthal, Patrick S. Sullivan, A. Blythe Ryerson, Eli S. Rosenberg – 14 January 2020 – Hepatitis C virus (HCV) infection is a leading cause of liver‐related morbidity and mortality, and more than 2 million adults in the United States are estimated to be currently infected. Reducing HCV burden will require an understanding of demographic disparities and targeted efforts to reduce prevalence in populations with disproportionate disease rates. We modeled state‐level estimates of hepatitis C prevalence among U.S.

Jennifer M. Kolb, Kendra Conzen, Michael Wachs, Joseph Crossno, Brandon McMahon, Maheen Z. Abidi, Elizabeth A. Pomfret, Michael Kriss – 14 January 2020

Jennifer M. Kolb, Kendra Conzen, Michael Wachs, Joseph Crossno, Brandon McMahon, Maheen Z. Abidi, Elizabeth A. Pomfret, Michael Kriss – 14 January 2020

Heather Bradley, Eric W. Hall, Elizabeth M. Rosenthal, Patrick S. Sullivan, A. Blythe Ryerson, Eli S. Rosenberg – 14 January 2020 – Hepatitis C virus (HCV) infection is a leading cause of liver‐related morbidity and mortality, and more than 2 million adults in the United States are estimated to be currently infected. Reducing HCV burden will require an understanding of demographic disparities and targeted efforts to reduce prevalence in populations with disproportionate disease rates. We modeled state‐level estimates of hepatitis C prevalence among U.S.

Vlad Ratziu, Arun Sanyal, Stephen A. Harrison, Vincent Wai‐Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P. Aithal, Kris V. Kowdley, Star Seyedkazemi, Laurent Fischer, Rohit Loomba, Manal F. Abdelmalek, Frank Tacke – 13 January 2020

Wei Li, Ying Xia, Jing Yang, Haitao Guo, Guoqing Sun, Arun J. Sanyal, Vijay H. Shah, Yongliang Lou, Xiaoqun Zheng, Naga Chalasani, Qigui Yu – 12 January 2020 – Alcoholic hepatitis (AH) is a severe inflammatory liver disease that develops in some heavy drinkers. The immune system in patients with AH is hyperactive and yet dysfunctional. Here, we investigated whether this immune‐dysregulated state is related to the alcoholic impact on immune checkpoints (ICPs).

Zhenhua Zhang, Martin Trippler, Catherine I. Real, Melanie Werner, Xufeng Luo, Stefan Schefczyk, Thekla Kemper, Olympia E. Anastasiou, Yvonne Ladiges, Juergen Treckmann, Andreas Paul, Hideo A. Baba, Lena Allweiss, Maura Dandri, Guido Gerken, Heiner Wedemeyer, Joerg F. Schlaak, Mengji Lu, Ruth Broering – 11 January 2020

Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, Matthias Kloor, Anna‐Lena Volckmar, Volker Endris, Ivo Buchhalter, Albrecht Stenzinger, Krzysztof Grzyb, Marit M. Grimsrud, Barbara Gornicka, Erik Seth, Gary M. Reynolds, Andre Franke, Daniel N. Gotthardt, Arianeb Mehrabi, Angela Cheung, Joanne Verheij, Johanna Arola, Heikki Mäkisalo, Tor J. Eide, Sören Weidemann, John C. Cheville, Giuseppe Mazza, Gideon M. Hirschfield, Cyriel Y. Ponsioen, Annika Bergquist, Piotr Milkiewicz, Konstantinos N. Lazaridis, Christoph Schramm, Michael P.